Facial Atrophy
Conditions
Keywords
Facial Atrophy, Autologous, Adult, Adipose Derived Stem Cells, Stromal Vascular Fraction, Collagenase
Brief summary
This phase two, randomized, double-blind study is designed to demonstrate the enhanced efficacy of SVF-enriched autologous facial fat grafts, in relation to standard, non-SVF enriched, facial fat grafts by evaluating volumetric retention and contour of the engrafted region over the course of one year.
Detailed description
Human Adipose Tissue is considered as a new source for Stromal Stem Cells and offers a large therapeutic potential for many rare and common diseases that impacts millions of patients worldwide. The Stromal Vascular Fraction (SVF) of Adipose Tissue is relatively easy to extract with minimally invasive procedures such as elective liposuction in large quantities and therefore may be a cost effective source for cellular therapies in a wide range of medical specialties. The term Facial Atrophy describes the lost of subcutaneous fat within the face and can be a result of the aging process as well as some pathological diseases. It can be corrected via autologous fat transfer but usually the majority of the grafted cells will die after 6-12 months. Several publications demonstrate that the addition of SVF cells to the graft may enhance the graft survival. This double blind, randomized study aims to demonstrated the efficacy of Antria Cell Preparation Process in autologous facial fat grafting.
Interventions
BIOLOGICALStromal Vasular Fraction
The stromal vascular fraction obtained from adipose tissue will be added to the graft
PROCEDUREBiopsy
A subgroup of each arm (2 subjects from each arm) will undergo a fat transfer behind each ear to be removed via biopsy after 12 months
Sponsors
Antria
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Female or Male, Age 18 to 70 years old 2. Subjects that are eligible for liposuction and facial fat grafting procedures for cosmetic purposes and facial atrophy. 3. Subjects must require augmentation to the infra-malar region. Furthermore, facial engraftment to additional, non-study related regions is optional, but not required. 4. Inframalar Atrophy Assessment Scale of 2 to 4 5. Facial volume defect range: 2 to 10 mL 6. Body Mass Index (BMI) between and including 22 and 29 7. Able to understand and provide written and verbal informed consent 8. Fitzpatrick Scale 1 to 6
Exclusion criteria
1. Currently taking or have taken None Steroid Anti-inflammatory Drugs (NSAIDs) within last two weeks or corticosteroids within the last six weeks prior to screening 2. Diagnosis of any of the following medical conditions: * Active malignancy (diagnosed within 5 years), except for treated non-melanoma skin cancer or other non-invasive or in-situ neoplasm (e.g. cervical cancer) * Active infection * Type I or Type II Diabetes * Skin/Bone deformities in the face, including scaring or hyperpigmentation within the graft site. 3. Subjects who are unlikely to comply with the protocol (e.g., uncooperative attitude, inability to return for subsequent visits, dementia, and/or otherwise considered by the Investigator to be unlikely to complete the study) 4. Subjects with a known drug or alcohol dependence within the past 12 months as judged by the Investigator 5. Dermal fillers or facial reconstruction within the past 24 months, Subjects must also refrain from such procedures during the duration of the study. 6. Subjects with major illnesses involving the renal, hepatic, cardiovascular, and/or nervous systems. 7. Subjects with elevated kidney and/or liver functions 8. Any other disease condition or laboratory results that in the opinion of the investigator may be clinically significant and render the subject inappropriate for the study procedure(s), may alter the accuracy of study results, or increase risk for subjects. 9. Subjects with life-expectancies less than 9 months 10. Subjects with known collagenase allergies 11. Subjects with idiopathic or drug-induced coagulopathy 12. Pregnant females 13. On radiotherapy or chemotherapy agents 14. Taking strong CYP450 inhibitors 15. Subjects with a history of keloids or hypertrophic scar formations 16. Previous treatment with any synthetic fillers in the inframalar area
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Volume retention | 12 months | To demonstrate that SVF administration, in concert with autologous facial fat grafts, is more efficacious, with regards to graft survival, than standard, non-SVF enhanced, autologous facial fat grafts |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants ith autologous facial fat grafts via laboratory results | 36 months | To monitor the safety of SVF administration along with autologous facial fat grafts via laboratory results |
| Changes in the quality of skin | 12 months | a blinded and independent investigator will assess any changes to the quality of skin |
Countries
United States
Outcome results
None listed